ProCE Banner Activity

Lenacapavir + Teropavimab and Zinlirvimab Every 6 Mo for Virologically Suppressed PWH

Capsule Summary
Conference Coverage

Phase Ib study demonstrated maintenance of virologic suppression for 26 weeks in PWH with a combination of LEN + the broadly neutralizing antibodies TAB (GS-5423) and ZAB (GS-2872).

Released: February 27, 2023

Expiration: February 26, 2024

Begin Activity



Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc.

ViiV Healthcare